OTHER × Lymphoma, Large-Cell, Anaplastic × Busulfan × Clear all
NCT00544115 2025-06-10

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

City of Hope Medical Center

Phase 2 Active not recruiting
260 enrolled 13 charts
NCT00003816 2021-08-13

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Roswell Park Cancer Institute

Phase 2/3 Completed
361 enrolled 16 charts
NCT00536601 2021-04-22

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Roswell Park Cancer Institute

Phase NA Completed
174 enrolled 17 charts
NCT00612716 2020-12-09

Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
6 enrolled 16 charts
NCT01093586 2019-01-23

Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Case Comprehensive Cancer Center

Phase 2 Completed
14 enrolled 22 charts
NCT00238368 2017-11-06

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
59 enrolled
NCT00301951 2017-10-12

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

University of California, San Francisco

Phase 1 Completed
7 enrolled
NCT00238433 2017-09-27

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

OHSU Knight Cancer Institute

Phase 2 Completed
37 enrolled 8 charts
NCT00513474 2017-05-25

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Massachusetts General Hospital

Phase 1 Completed
46 enrolled 11 charts
NCT01427881 2017-05-19

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Completed
43 enrolled 14 charts
NCT01118013 2017-03-24

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Alliance for Clinical Trials in Oncology

Phase 2 Terminated
6 enrolled 5 charts
NCT01959477 2015-08-13

Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
33 enrolled
NCT00818961 2013-12-18

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Northside Hospital, Inc.

Phase 2 Terminated
36 enrolled 16 charts
NCT00002502 2013-06-27

Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
NCT00787761 2012-10-01

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Northside Hospital, Inc.

Phase 2 Completed
24 enrolled 13 charts
NCT01177371 2010-08-09

High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma

Case Comprehensive Cancer Center

Phase 2 Completed
13 enrolled